ArticleBMC cancer2025
Effect of chemotherapeutic drugs and cytochalasin B on tunneling nanotubes in U87 MG cells.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Tunneling nanotubes: a new dimension of intercellular communication and recent progress.Cell communication and signaling : CCS · 2026Review
- From energy provision to protein synthesis: Tunnelling nanotubes as mediators of intercellular metabolic cooperation in cancer.FEBS open bio · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intercellular communication in the tumor microenvironment has a major impact on therapeutic outcomes. In particular, highly aggressive cancers such as glioblastoma benefit from efficient cellular communication by developing resistance to therapy or by infiltrating surrounding tissue to escape radiotherapy. Tiny membrane tunnels, such as tunneling nanotubes (TNTs), can serve as an effective communication tool for tumor cells. With these structures, the cells can build a large network that allows them to react and adapt to their environment as quickly as possible, thereby combating the therapy. In this study, we investigated the effects of chemotherapeutic agents on TNT networks in U87 MG cells to determine if they affect the number of TNTs and, consequently, possible therapeutic outcomes. The effect of drugs on TNT stability may be related to their effects on actin and tubulin, which are known stabilizers of membrane structures. Therefore, we also analyzed the cytoskeletal content of TNTs in U87 MG cells and examined the effect of the actin polymerization inhibitor cytochalasin B (CytoB) on TNT formation and networks. CytoB reduced the number of TNTs in this study, suggesting that actin, as a cytoskeletal component, is required for developing TNT networks. In contrast, the chemotherapeutic agents temozolomide (TMZ) and cytarabine (AraC) do not affect TNTs and actin content. As TNT networks are closely linked to increased therapy resistance of certain tumors, we believe that the lack of suppression of TNTs is a major problem in current glioblastoma therapy and should be a target for further research in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.